Lupin Q1 FY27: record revenue and EBITDA; guides margins lower on US competition

Mgmt Guided Margin PressureOrder Pipeline DisclosedAnalyst Day Multiyear TargetsInvestor Communications View source PDF Explain this filing

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.3%1-day move

₹2263.60

prior close

₹2268.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.0+0.3-0.1-0.2-1.3-0.2-1.4-1.7-2.7—————

Up moveDown movePending

AI summary

Record Q1: revenue rose 32% YoY to Rs 8,277 crore, EBITDA up 50% to Rs 2,464 crore with margins at 30% (vs 26.6%). US grew 30% to USD 366 million but guides FY27 US at USD 1.1-1.2 billion due to competition on Mirabegron and Tolvaptan. Full-year EBITDA margin guided at around 25%, below current quarter. India grew 13.9%, Europe up 48%, emerging markets up 52%. Net cash fell to Rs 2,831 crore post VISUfarma acquisition. Plans 50 plus US launches over three years including biosimilars and 505(b)(2) products.

Likely market impact

Strong quarter but full-year margin guidance of about 25% is below current 30%, signaling near-term pressure from US competition on key products.